RT Journal Article SR Electronic T1 Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network JF Journal of Clinical Pathology JO J Clin Pathol FD BMJ Publishing Group Ltd and Association of Clinical Pathologists SP 668 OP 672 DO 10.1136/jclinpath-2020-206800 VO 74 IS 10 A1 Caterina Fumagalli A1 Elena Guerini-Rocco A1 Fiamma Buttitta A1 Pierluigi Iapicca A1 Wenqi You A1 Michela Mauri A1 Lara Felicioni A1 Giancarlo Troncone A1 Umberto Malapelle A1 Aldo Scarpa A1 Giuseppe Zamboni A1 Daniele Calistri A1 Massimo Barberis A1 Antonio Marchetti YR 2021 UL http://jcp.bmj.com/content/74/10/668.abstract AB Introduction BRCA tumour testing is a crucial tool for personalised therapy of patients with ovarian cancer. Since different next-generation sequencing (NGS) platforms and BRCA panels are available, the NGS Italian Network proposed to assess the robustness of different technologies.Methods Six centres, using four different technologies, provided raw data of 284 cases, including 75 cases with pathogenic/likely pathogenic variants, for a revision blindly performed by an external bioinformatic platform.Results The third-party revision assessed that all the 284 raw data reached good quality parameters. The variant calling analysis confirmed all the 75 pathogenic/likely pathogenic variants, including challenging variants, achieving a concordance rate of 100% regardless of the panel, instrument and bioinformatic pipeline adopted. No additional variants were identified in the reanalysis of a subset of 41 cases.Conclusions BRCA tumour testing performed with different technologies in different centres, may achieve the realibility and reproducibility required for clinical diagnostic procedures.